Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: A real world study

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 216-224

  Lampropoulos, Christos E ^a   Orfanos, Philippos ^a   Bournia, Vasiliki Kalliopi ^a   Karatsourakis, Theofilos ^a   Mavragani, Clio ^a   Pikazis, Dimitrios ^a   Manoussakis, Menelaos N ^a   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a   Vlachoyiannopoulos, Panayiotis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adverse events; Biologic agents; Disease modifying anti rheumatic drugs; Infections; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMMUNICABLE DISEASES; COMPARATIVE STUDY; GREECE; INCIDENCE; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COMMUNICABLE DISEASES; FEMALE; GREECE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929939135     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
2. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
3. LIPSKY PE, van der HEIJDE DM, St CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
4. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
5. DADOUN S, ZEBOULON-KTORZA N, COMBES-CURE C et al.: Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013; 80: 29-33.
6. ZHANG N, WILKINSON S, RIAZ M, ÖSTöR, AJ, NISAR MK: Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis?. A systematic literature review. Clin Exp Rheumatol 2012; 30: 962-71.
7. KOURBETI IS, ZIAKAS PD, MYLONAKIS E: Biological therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis. Clin Infect Dis 2014; [In press].
8. RAMIRO S, GAUJOUX-VIALA C, NAM JL et al.: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-35.
9. LISTING J, KEKOW J, MANGER B et al.: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF-α inhibitors and rituximab. Ann Rheum Dis 2013; 73: 149-53.
10. GARDAM MA, KEYSTONE EC, MENZIES R et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
11. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
12. STRANGFELD A, LISTING J, HERZER P et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-44.
13. SALLIOT C, GOSSEC L, RUYSSEN-WITRAND A et al.: Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46: 327-34.
14. GREENBERG JD, REED G, KREMER JM et al.: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-6.
15. DIXON WG, HYRICH KL, WATSON KD, LUNT M, GALLOWAY J, USTIANOWSKI A: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
16. GALLOWAY JB, HYRICH KL, MERCER LK et al.: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
17. CURTIS JR, PATKAR N, XIE A et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33.
18. MARIETTE X, GOTTENBERG JE, RAVAUD P, COMBE B: Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
19. RAMOS-CASALS M, BRITO-ZERóN P, MUñOZ S et al.: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51.
20. PEREZ-ALVAREZ R, PEREZ-DE-LIS M, DIAZ-LAGARES C et al.: Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256-64.
21. HARRISON MJ, DIXON WG, WATSON KD et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
22. ZINTZARAS E, VOULGARELIS M, MOUTSOPOULOS HM: The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
23. MARIETTE X, TUBACH F, BAGHERI H et al.: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69: 400-8.
24. GEBOREK P, BLADSTRöM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
25. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
26. WOLFE F, MICHAUD K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
27. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
28. van de PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
29. WEISMAN MH, PAULUS HE, BURCH FX et al.: A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 2007; 46: 1122-5.
30. WIENS A, CORRER CJ, VENSON R, GROCHOCKI MC, OTUKI MF, PONTAROLO R: A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 2009; 28: 1365-73.
31. WOLFE F, CAPLAN L, MICHAUD K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34.
32. GALLOWAY JB, MERCER LK, MOSELEY A et al.: Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
33. ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45: 1294-7.
34. SCHNEEWEISS S, SETOGUCHI S, WEINBLATT ME et al.: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
35. KIEVIT W, FRANSEN J, ADANG EM et al.: Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
36. GRIJALVA CG, KALTENBACH L, ARBOGAST PG, MITCHEL EF Jr, GRIFFIN MR: Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010; 49: 82-90.
37. CANTINI F, BOCCIA S, GOLETTI D et al.: HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol 2014; 2014: 926836.
38. ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
39. DREYER L, MELLEMKJÆR L, ANDERSEN AR et al.: Incidences of overall and site specific cancers in TNF-α inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013; 72: 79-82.
40. LOPEZ-OLIVO MA, TAYAR JH, MARTINEZ-LOPEZ JA et al.: Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308: 898-908.
41. THOMPSON AE, RIEDER SW, POPE JE: Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis. Arthritis Rheum 2011; 63: 1479-85.
42. CRUZ FERNáNDEZ-ESPARTERO M, PéREZ-ZAFRILLA B, NARANJO A et al.: Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011; 41: 524-33.
43. LJUNG L, SIMARD JF, JACOBSSON L, RANTAPää-DAHLQVIST S, ASKLING J: Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012; 64: 42-52.
44. LUNT M, WATSON KD, DIXON WG: No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010; 62: 3145-53.
45. BAECKLUND E, ILIADOU A, ASKLING J et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
46. AU K, REED G, CURTIS JR et al.: High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785-91.
47. van DARTEL SA, FRANSEN J, KIEVIT W et al.: Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2013; 52: 1052-7.
48. DIXON WG, ABRAHAMOWICZ M, BEAUCHAMP ME et al.: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71: 1128-33.
49. LISTING J, KEKOW J, MANGER B et al.: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF-α inhibitors and rituximab. Ann Rheum Dis 2015; 74: 415-21.
50. EMERY P, GALLO G, BOYD H et al.: Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2014; 32: 653-60.
51. DROSOS AA, LANCHBURY JS, PANAYI GS, MOUTSOPOULOS HM: Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic and serologic study. Arthritis Rheum 1992; 35: 745-8.
52. SOKKA T, HETLAND ML, MäKINEN H et al.: Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008; 58: 2642-51.
53. DIXON WG, SYMMONS DP, LUNT M, WATSON KD, HYRICH KL, SILMAN AJ: Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904.
54. VERSTAPPEN SM, BAKKER MF, HEURKENS AH et al.: Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 2010; 69: 1044-8.
55. BURMESTER GR, KIVITZ AJ, KUPPER H et al.: Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014 Feb 18 [Epub ahead of print].
56. CAPELL HA, MADHOK R, PORTER DR et al.: Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66: 235-41.